secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempus AI, Inc. (TEM)
CIK:        0001717115
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001193125-25-090062
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempus AI inks deals with AstraZeneca, Pathos for $200M data licensing, $35M fee for oncology AI model
--------------------------------------------------------------------------------

- AstraZeneca pays Tempus $35M under MSA for foundational multimodal oncology model developed by Pathos using Tempus de-identified data.
- Tempus and Pathos sign Order Form: Pathos pays $200M data license fees over 3 years ($50M upfront); Tempus receives license to use model.
- Pathos may pay up to 50% of data license fees in shares of Pathos Series D Preferred Stock at its discretion.
- Tempus pays Pathos $35M in consideration for Pathos' commitments under the Pathos Master Agreement.
- Syndicate led by AstraZeneca will execute stock purchase agreement with Pathos in preferred stock financing round.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1717115/000119312525090062/0001193125-25-090062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1717115/000119312525090062/d944168d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-090062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer